VEGFA and wet macular degeneration: Targeting VEGFA by anti‐VEGFA agents significantly improved the treatment of wet AMD outcome and, in fact, led to its removal from the list of incurable diseases.2 Bevacizumab (Avastin®), ranibizumab (Lucentis®) and aflibercept (Eylea®) are used to prevent CNV activity.